enVVeno Medical Corporation (NVNO)
- Previous Close
5.23 - Open
5.32 - Bid 5.03 x 100
- Ask 5.26 x 100
- Day's Range
5.11 - 5.32 - 52 Week Range
2.51 - 6.97 - Volume
46,926 - Avg. Volume
134,733 - Market Cap (intraday)
68.982M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-1.91 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
www.envveno.comRecent News: NVNO
Performance Overview: NVNO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVNO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVNO
Valuation Measures
Market Cap
69.65M
Enterprise Value
24.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.00
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-34.94%
Return on Equity (ttm)
-55.38%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-23.52M
Diluted EPS (ttm)
-1.91
Balance Sheet and Cash Flow
Total Cash (mrq)
46.41M
Total Debt/Equity (mrq)
3.04%
Levered Free Cash Flow (ttm)
-10.37M